Modafinil is named as an intervention in 2 current clinical trials in our Netherlands and Canada registers. 2 are recruiting patients now. The most common phase is Phase 2/3. The sponsor with the most trials is Radboud University Medical Center (1). The most-studied condition is Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis).
Modafinil was first approved in the US on 24 Dec 1998. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
NCT07582458 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue
|
Phase 2/3 | Recruiting | Radboud University Medical Center | Netherlands |
|
Modafinil to Improve Fatiguability
NCT05333250 · ClinicalTrials.gov ↗ · Cancer-related Cognitive Difficulties, Cancer-related Problem/Condition, Fatigue
|
Phase 1/2 | Recruiting | Ottawa Hospital Research Institute | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
6 single-substance products containing Modafinil on the HPRA medicines list.
No entry for Modafinil in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Radboud University Medical Center | 1 |
| Ottawa Hospital Research Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Netherlands | 1 | 1 |
| Clinical trials in Canada | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Netherlands and Canada registers name Modafinil as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in Netherlands and 1 with sites in Canada. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Radboud University Medical Center (1) and Ottawa Hospital Research Institute (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 6 single-substance products containing Modafinil, for example Modafinil Bluefish 100 mg tablets (Bluefish Pharmaceuticals AB). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Modafinil has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Modafinil works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Modafinil works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Modafinil (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.